10 10 14, the second Abbott science and technology day focusing on new technologies of heart health management and diagnosis and treatment was held in Beijing.
Facing the "number one killer" cardiovascular disease that harms human health, Abbott is helping the diagnosis and treatment of cardiovascular diseases in China with solutions covering the whole life cycle and skills training for doctors at different stages.
China Cardiovascular Disease Report 20 18 shows that the mortality rate of cardiovascular diseases in China ranks first, higher than that of tumors and other diseases, accounting for more than 40% of the deaths of residents, and the prevalence rate and mortality rate are still on the rise. At present, there are about 290 million patients with cardiovascular diseases in China, accounting for 1/5 of the total population.
With the increasing number of elderly cardiovascular patients, the application scenarios are becoming more and more complex, and the requirements for medical products are getting higher and higher. Advanced technology and product line covering the whole life cycle, the market challenge is Abbott's first chance to win the market.
Create a product line for the whole life cycle of the heart
Abbott has a complete product line in the field of heart, covering cardiovascular field (coronary artery and peripheral vascular intervention), rhythm management, cardiac electrophysiology and heart failure, and structural heart disease.
In the field of coronary intervention therapy,
In the field of rhythm management, Abbott has recently launched new products frequently:
Abbott also has an implantable ECG event monitor Confirm Rx to monitor abnormal heart rate? HeartMate 3, used to replace the heart, so that patients with heart failure don't have to wait in line for heart donation? Cardiac auxiliary pump (left ventricular auxiliary device) can effectively shorten the operation time and improve the overall solution of atrial fibrillation.
* confirm Rx? What about HeartMate 3? Not yet listed in China.
In the field of structural heart disease,
Abbott provides a full range of structural cardiac occluder and valve solutions for surgery and interventional therapy. MitraClip, the world's first percutaneous mitral valve repair system launched by Abbott, has made outstanding income contributions.
"Abbott insists on the love for patients, the craftsmanship of products, and the love for doctors, and has created corresponding solutions. While helping patients solve health problems, it will bring benefits to society and enrich patients and their families. " Yu Jinbao, vice president of Abbott's Asia-Pacific Heart Rate Management Business Department, told Medical Trends that this is Abbott's "half-hearted" insistence.
"Try first" and innovate new products.
Regarding the promotion of new products in China market, Yu Jinbao said frankly: "Technology learning itself needs cycles, processes and time points. Abbott has no illusions that new technologies or products will be fully popularized in China overnight. In the process of popularization, we hope to be responsible for patients and doctors, achieve the expected therapeutic effect, and try to avoid detours. "
Therefore, Abbott's new products are usually tried in some hospitals first, and then further promoted to the whole country after accumulating experience.
Lack of doctors and low awareness rate of patients are two major challenges in the cardiovascular equipment market in China.
(1) Multi-level training, "Give people fish"
The aging trend in China will make more and more people face the challenge of heart disease in the future, and doctors and hospitals will be overloaded. Training more high-quality doctors is the key, and Abbott has made a lot of efforts to this end:
It is very rare for trained doctors to have the opportunity to implant guide wires, balloons and stents in simulated blood vessels. The consumables used are all real materials, so that trained doctors can get the closest real experience.
"We found that the level of doctors in China, especially in big cities, is already very high. At present, the greater demand is how to make county doctors safely and effectively deal with the most common diseases in their daily work. "
Therefore, Tan Minjie, vice president of Abbott's Cardiovascular Business Department in Asia Pacific, believes that if more third-and fourth-line doctors can handle 70%-80% of common diseases in local hospitals, it will really help more patients in China, which will also promote the transformation of Abbott's training direction.
Crossroads were originally designed to train doctors in large and medium-sized hospitals, but for doctors in remote areas, the cost of crossing roads in Shanghai is too high. With the proposal of "sinking medical resources", Abbott adjusted the location of the intersection on 20 15, and put forward that the intersection should be grassroots.
Up to now, Crossroads has organized more than 80 core courses in Shanghai, and also co-organized training with 22 hospitals to train local grassroots doctors.
In terms of arrhythmia, Abbott launched a "Youth Training Camp" for grassroots doctors, with the aim of standardizing the training of young doctors and training more doctors with stronger professional ability.
Abbott Beijing Advanced Technology Center also provides training for doctors in primary hospitals.
"Of course, training has different levels of coverage," Tan Minjie said. For doctors in top three hospitals, Abbott emphasizes mobilizing global resources, supporting them to participate in large-scale research on a global scale, and enhancing their global voice. These clinical studies are not limited to Abbott's products, but may also be clinicians' exploration of medicine, such as improving surgical methods.
(2) Education first to improve patients' cognition.
Compared with other common diseases, patients' awareness rate, cognition and doctor's advice execution are still low. For example, few hypertensive patients in China take antihypertensive drugs in strict accordance with the doctor's advice.
Yu Jinbao thinks: "Healthy China starts with healthy individuals. However, at present, the awareness rate of cardiovascular diseases is less than 50%, and the diagnosis rate is even lower than 40%. Compliance with medical advice is very low. "
Therefore, strengthening public education, making patients know their own situation, actively preventing potential diseases and guiding patients to carry out corresponding treatment are closely related to the improvement of medical environment.
"Everything is education first. You will find that in all social forms, education has changed society, changed people's ideas, changed people's cognition and changed the pace of the whole society. For enterprises, it is the same to raise public awareness of new products, and education is needed first. " Yu Jinbao said.
Abbott is also raising public awareness through media promotion and knowledge popularization activities.
These not only bring social value and enterprise value to Abbott, but also bring some new directions to R&D (such as the demand of Dr. China and the further improvement of products), and also make Abbott more aware of what publicity work should be done when products enter the market.
Tan Minjie explained: "Because instruments are different from drugs, instruments need to be operated by doctors. When choosing a new product, doctors need to know the different technical characteristics, size specifications and precautions of the new product. There may be some slight differences between the products of each company and even different series of products of the same company. These small differences are very important for patients and doctors. "
As a part of promoting "healthy China", Abbott has been deeply involved in the China market for many years. At present, there are four factories, three R&D centers, a Beijing training center and a Shanghai training center in China, and several offices and regional centers in China for staff training and doctor training, which continuously meet the challenges and needs of China's medical and health undertakings.
It is understood that Abbott's future investment in the China market will also adhere to "bringing in and going out" and gradually bring more advanced technologies to China; Improve the level of doctors and employees and promote international integration.
Generally speaking, Abbott provides not only products, but also complete solutions in the field of health, which far exceeds the value brought by the products themselves and brings a paradigm for the development of other enterprises.
end